Sound Bioventures — Full Portfolio
22 tracked investments · listed companies and verified rows first
AbolerIS Pharma develops therapeutic approaches that regulate the immune system by inducing immune tolerance while preserving useful immune responses, targeting inflammatory, autoimmune, and degenerative diseases.
BiotechHealthtech
Ignacio Anegon(Co-founder, Senior Consultant & SAB Member)inCarole Guillonneau(Co-founder & Head of Research)inFrançois-Xavier Hubert(Co-founder, Past President & Board Member)
Co-investorsCriteria Bio VenturesNewton BiocapitalSambrinvestWallonie Entreprendre
AnaCardio is a Swedish clinical-stage biopharmaceutical company developing novel drugs to treat heart failure, with its lead program AC01 in phase 1b/2a clinical development.
BiotechHealthtechMedical DevicesStockholm, SE
Lars H. Lund(Founder)
Co-investors3B Future Health FundIndustrifondenNovo HoldingsPureos Bioventures
Arthex Biotech develops antisense RNA compounds to treat diseases with unmet medical needs.
AI & Machine LearningBiotechMedical Devices
Beatriz Llamusí(Chief Scientific Officer & Co-Founder)in
Co-investorsBpifranceColumbus Venture PartnersHadean VenturesAdBio partnersInvivo Capital Partners
Teitur Trophics is a biotech company developing therapies that target the sortilin family of receptors (SorCS-receptor biology) to activate the brain's natural survival pathways and preserve brain function.
BiotechDeep TechHealthtechLongevityAarhus, DK
Simon Mølgaard(Co-founder & CEO)inAnders Dalby(Co-founder)inMathias Ollendorff(Co-founder)inSimon Glerup(Co-founder)in
Co-investorsIndustrifondenP53 InvestInnovestorSunstone Capital
Theolytics develops systemically deliverable immunotherapies based on oncolytic adenoviruses designed to target solid tumours and their supporting microenvironment.
BiotechHealthtech
Co-investorsEpidarex CapitalOxford Science EnterprisesTaiho Ventures, LLCM Ventures
VarmX develops VMX-C001, a therapeutic medicine for treating severe bleeding in patients on Factor Xa anticoagulants and for emergency surgery settings.
BiotechHealthtechMedical Devices
Pieter ReitsmainJohn Glasspool(Chief Executive Officer)in
Co-investorsYsios CapitalBioGeneration VenturesEICEQT Life SciencesInkefUNIIQ+2 more
Artax Biopharma is a Phase 2 clinical-stage biotechnology company developing first-in-class oral small-molecule Nck modulators that target T cell receptor Signal 1 activation to treat autoimmune diseases without causing immunosuppression.
BiotechHealthtechCambridge, US
Damia Tormo(President, CEO, Treasurer and Founder)inJoe Suarez(Executive Officer)Maria Nichol(Executive Officer)inRobert W. Armstrong, Ph.D.(Executive Officer, Director)Rob Armstrong(CEO)in
BoardAndre Hoekema(Director)
Co-investorsAdvent Life SciencesColumbus Venture Partners
Biotech Finances is a French-language news and analysis publication covering the biotech, pharma and medtech industries, focusing on financing, mergers and acquisitions, clinical developments and listed biotech valuations.
BiotechMedia & Entertainment
BioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals.
BiotechMedia & EntertainmentMedical Devices
BOOST Pharma is developing BT-101, a mesenchymal stem cell therapy for Osteogenesis Imperfecta (brittle bone disease) in children, based on research from Karolinska Institutet in Sweden.
BiotechHealthtechStockholm, SE
Lilian Walther Jallow(Co-founder & CDO)Cecilia Gotherstrom(Co-founder and member of SAB)Hans T. Schambye(Chief Executive Officer)Tony Hall(Chief Medical Officer)Louise Himmelstrup(Chief Regulatory Officer)
Co-investorsIndustrifonden
Born2Invest is an online financial news publication covering markets, investing, crowdfunding, biotechnology, and cryptocurrency for a general investor audience.
FintechMedia & Entertainment
Breye Therapeutics is a biopharmaceutical company developing medicines for ophthalmologic and metabolic diseases, leveraging expertise in clinical development, manufacturing, and regulatory pathways.
BiotechMedical Devices
Ulrik Mouritzen(CEO)
Co-investorsNovo Holdings
Cytospire Therapeutics develops multispecific antibodies and next-generation γδ T cell engagers designed to direct innate and adaptive immune effector cells as an alternative to CD3-based engagers.
BiotechHealthtech
Co-investorsCriteria Bio VenturesLifeArc VenturesMedical Incubator Japan K.K.Modi VenturesPathway Bioventures
Hoama Group develops care and living communities for older adults, including specialized facilities for elderly deaf people using British Sign Language.
HealthtechMedia & EntertainmentSocialStaplehurst, GB
Nephrodi is a biotechnology company developing treatments for kidney conditions, including the rare disease Nephrogenic Diabetes Insipidus (NDI).
BiotechHealthtechMedical DevicesSeattle, US
Jeff M. Sands, M.D.(Executive Officer)Jeff M. Sands(Chief Medical Officer & Founder)Janet D. Klein(Director of Biology & Founder)Rachael Hagan(President & Chief Executive Officer)inFred Callori(Director)Donna See(Director)
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
AbolerisArthexARTHEx BiotechBreye TherapeuticsCytospire TherapeuticsShorturlTeitur
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.